48 Weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 8, 2006, Pages 1171-1178

  Hui, C K ^a   Lai, L S W ^b   Lam, P ^a   Zhang, H Y ^a   Fung, T T ^c   Lai, S T ^d   Wong, W M ^e   Lo, C M ^a   Fan, S T ^a   Leung, N ^f   Lau, G K K ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Caritas Medical Centre Hong Kong   (Hong Kong)

^c KWONG WAH HOSPITAL   (Hong Kong)

^d PRINCESS MARGARET HOSPITAL   (Hong Kong)

^e St Paul's Hospital Hong Kong   (Hong Kong)

^f ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; EMTRICITABINE; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HEPATITIS B; HONG KONG; HUMAN; LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SEROCONVERSION; STATISTICAL ANALYSIS; THYROTOXICOSIS;

ADULT; ALANINE TRANSAMINASE; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33646860152     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02887.x     Document Type: Review

References (27)

1. Lau GKK. Hepatitis B infection in China. In :Clinics in Liver Disease 2001 5 :361 79
2. Wong D Cheung R O'Rourke K Naylor C Detsky A Heathcote J. Effect of α-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1991 114 :629 34.
3. Lau GK Piratvisuth T Luo KX, et al. Peginterferon alfa-2a (40 kD) (PEGASYS) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg positive chronic hepatitis B: results from a large, multinational study. N Eng J Med 2005 352 :2682 95.
4. Janssen HL van Zonneveld M Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005 365, 123 9.
5. Lau GK He ML Fong DY, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 2002 36 :702 9.
6. Ishak K Baptista A Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 :696 9.
7. Hui CK Sun J Au WY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005 42 :813 9.
8. Hui CK Cheung WW Au WY, et al. Hepatitis B reactivation after withdrawal of preemptive lamivudine in patients with hematological malignancy upon completion of cytotoxic chemotherapy. Gut 2005 154 :1597 603.
9. Lau GK Cooksley H Ribeiro RM, et al. Randomized, double-blind study comparing adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy versus ADV alone in HBeAg (+) chronic hepatitis B: efficacy and mechanisms of treatment response. Hepatology 2004 38 :272A.
10. Bailon P Palleroni A Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001 12 :195 202.
11. Pegintron. Peginterferon Alfa-2b. Product Monograph. Kenilworth, NJ :Schering-Plough Corporation, 2001.
12. Hui CK Lau GKK. Peginterferon alfa-2a (40 kD) (Pegasys) for hepatitis B. Expert Review of Anti-Infective Therapy 2005 3 :495 504.
13. Cooksley WG Piratvisuth T Lee SD, et al. Peinterferon alfa-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hep 2003 10 :298 305.
14. Lai CL Chien RN Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Eng J Med 1998 339 :61 68.
15. Dienstag JL Schiff ER Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Eng J Med 1999 341 :1256 63.
16. Marcellin P Lau G Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Eng J Med 2004 351, 1206 17.
17. Chan LY Leung N Hui AY, et al. A randomized controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon alfa-2b and lamivudine with lamivudine alone. Ann Intern Med 2005 142 :240 50.
18. Foster GR. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Therap 2004 20 :825 30.
19. Lindsay KL Trepo C Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001 34 :395 403.
20. Zaman A Fennerty MB Keefe EB. Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C. Aliment Pharmacol Ther 2003 18 :661 70.
21. Janssen HL Gerken G Carreno V, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999 30 :238 43.
22. Chang TT Gish R de Man R, et al. Entecavir is superior to lamivudine for the treatment of HBeAg (+) chronic hepatitis B: results of a phase III study ETV-022 in nucleoside analogue-naïve patients. Hepatology 2004 40 Suppl. 1 193A.
23. Lai CL Leung N Teo EK, et al. A 1-year trial of telbivudine, lamivudine and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005 129 :528 36.
24. Yeoh EK Chang WK Kwan JPW. Epidemiology of viral hepatitis B infection in Hong Kong. In :Lam SK Lai CL Yeoh EK, eds. Viral Hepatitis in the Western Pacific Region: Vaccine and Control. Singapore :World Scientific, 1984 :33 44.
25. Bertoletti A Naoumov NV. Translation of immunological knowledge into better treatments of chronic hepatitis B. J Hepatol 2003 39 :115 24.
26. Lok AS Lai CL Wu PC Leung EK. Long-term follow-up in a randomized controlled trial of recombinant alpha-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988 2 :298 302.
27. Lok AS Wu PC Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992 102 :2091 7.